Cardioprotection by a nonerythropoietic, tissue-protective peptide mimicking the 3D structure of erythropoietin
Ueba H, Brines M, Yamin M, Umemoto T, Ako J, Momomura S, Cerami A, Kawakami M
PNAS (2010)
The 11-amino-acid helix B surface peptide that became ARA-290 inhibits TNF-α-induced cardiomyocyte apoptosis by approximately 80% and reduces in-vivo cardiac apoptosis by approximately 70% in a hamster dilated-cardiomyopathy model — extending the IRR mechanism into a cardiac-protection indication that did not progress to clinical development.
This is the cardiac-extension mechanism paper for the helix B surface peptide that became ARA-290 (cibinetide), published in PNAS in 2010 by Ueba, Brines, Cerami, and colleagues. The paper extends the Brines et al. 2008 IRR design framework into a cardiac-protection context, characterizing the helix B surface peptide (HBSP) in two model systems: (1) cultured neonatal rat cardiomyocytes exposed to tumor necrosis factor-α (TNF-α) as an apoptosis stimulus, and (2) a hamster model of dilated cardiomyopathy as an in vivo heart-failure phenotype.
The cardiomyocyte results recapitulate the in-vitro side of the IRR story. HBSP inhibited TNF-α-induced apoptosis in cultured neonatal rat cardiomyocytes by approximately 80%, comparable to the protection conferred by full-length erythropoietin. The mechanism routes through Akt-dependent survival signaling — Akt phosphorylation, ERK1/2 activation, and STAT3 activation were observed in the protected cells, and pharmacological Akt inhibition abolished the protective effect. The receptor-decoupling property that distinguishes HBSP from EPO is preserved: the peptide did not stimulate erythropoiesis in vivo, consistent with engagement of the heteromeric tissue-protective receptor (EPOR + CD131) rather than the homodimeric (EPOR)₂ that drives red-cell production.
The in-vivo cardiac results extend the story into chronic heart failure. In the hamster dilated-cardiomyopathy model, HBSP administration suppressed cardiomyocyte apoptosis in the failing heart by approximately 70%, reduced serum creatine kinase activity (a marker of ongoing myocardial injury), and downregulated atrial natriuretic peptide expression (a marker of heart-failure progression). The authors framed the readout as evidence that HBSP could in principle support a cardiac-protection indication — particularly post-myocardial-infarction left-ventricular preservation and chronic heart-failure cardiomyocyte rescue — without the hematocrit-elevation thrombotic risk that classical EPO's cardiac applications had been limited by in human trials.
This is the foundational receptor-pharmacology paper for the cardiac branch of the ARA-290 mechanism story, cited in the cardiac context throughout the ARA-290 peptide page and the peptide receptor pharmacology atlas.
The paper is preclinical in its entirety — no human cardiac trial of ARA-290 / cibinetide has ever been completed, and the cardiac-protection indication did not progress to clinical development in the Araim Pharmaceuticals pipeline. The TNF-α-stimulated cardiomyocyte apoptosis model captures one mechanism of cardiac injury (cytokine-driven apoptotic loss) but does not generalize to the full range of cardiac injury patterns in human heart failure — ischemic, reperfusion, hypertrophic, valvular, and arrhythmic mechanisms all involve cardiomyocyte stress that does not necessarily route through the same IRR-Akt axis. The hamster dilated-cardiomyopathy model is a recognized in-vivo system for heart-failure pharmacology but is a far cry from a human chronic-heart-failure population, and the readout endpoints (cardiomyocyte apoptosis, serum CK, ANP expression) are surrogate markers rather than clinical outcomes (ejection fraction, hospitalization, mortality). The receptor-engagement story rests on the broader IRR framework from Brines 2008; the structural biology of the proposed EPOR + CD131 heterodimer is less mature than for any conventional GPCR. The Araim development program produced legitimate Phase II signals in sarcoidosis-associated small-fiber neuropathy and diabetic peripheral neuropathy, but the cardiac indication that the 2010 paper's mechanism would have anticipated was never advanced; commercial development of the molecule stalled in the late 2010s. Sponsorship by Araim Pharmaceuticals is disclosed; co-authors Brines and Cerami are Araim co-founders. The cardiac-protection biology characterized in this paper is one of the IRR-program signals that did not become a clinical-development indication — part of the broader pattern that the /peptides/ara-290 page assembles around the molecule's stalled trajectory.
07·Member discussion
No member discussion yet.
Member-only conversation lives here — cycle notes, practitioner commentary, pattern-matching. Be the first paying member to start the thread.